Drug Discovery & Pharmaceuticals

RSS

Gyros Protein Technologies adds Gyrolab® Biomarker Kits to expand range of ready-to-use kits and reagents

Gyros Protein Technologies AB today introduced Gyrolab® Human Cytokine Kit Reagents, the first in a range of new biomarker kits.

From Gyros Protein Technologies AB 30 Nov 2022

Chemical-biological method to upcycle plastic waste into pharmacologically useful products

Plastic waste is one of the most significant ecological and economic problems of our time. In the journal Angewandte Chemie, a research team has now introduced a chemical–biological method for upcycling polyethylene waste: catalytic cleavage is used to make carboxylic diacids that are subsequently converted into pharmacologically useful natural products by genetically engineered fungi.

29 Nov 2022

Tackling epilepsy with a potential new drug

One of the epilepsy types that are most prevalent worldwide is temporal lobe epilepsy (TLE). Although there are symptomatic medications available, one-third of TLE patients are still not responding to the current course of treatment, necessitating the urgent need for new drug targets.

25 Nov 2022

AI creates artificial DNA to control cell protein production

Researchers at Chalmers University of Technology in Sweden have developed synthetic DNA that uses artificial intelligence to control the production of proteins in cells.

25 Nov 2022

Novel approach increases the protein production efficiency of synthetic mRNAs

A group of synthetic biologists at the Hong Kong University of Science and Technology (HKUST) recently figured out a way to improve the efficiency of synthetic mRNA protein production by up to tenfold.

24 Nov 2022

Molecular motion of “undruggable” proteins reveals drug-binding sites

“Undruggable” proteins, whose structures and roles in disease are known but who appear unable to be targeted by drugs that will bind to them, present some of the hardest problems in disease treatment.

23 Nov 2022

Optibrium appoints Ian Smith as Chief Technology Officer

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the appointment of Ian Smith as Chief Technology Officer (CTO), the latest in a number of senior-level hires for the Company.

From Optibrium Ltd. 23 Nov 2022

Atypical antibody shows extremely potent zika-resistant activity

A group of researchers led by Weill Cornell Medicine, New York-Presbyterian, and National Institutes of Health (NIH) investigators has discovered an unusual type of antibody that, even at extremely low concentrations, neutralizes the Zika virus and renders the virus infection undetectable in preclinical models.

22 Nov 2022

The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

From The Native Antigen Company 21 Nov 2022

IBS team uncovers new antiviral compounds derived from two Korean native plants

Codonopsis lanceolata, more commonly referred to as "deodeok", is used as a medicinal herb in South Korea.

14 Nov 2022

Understanding immune cell function to improve vaccine efficacy

The immune system’s capacity to remember defeated disease-causing germs and avoid recurrent infections is still poorly understood, but a new study published in Science Immunology fills in some gaps.

From Rutgers University 8 Nov 2022

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

From The Native Antigen Company 7 Nov 2022

Georgia Tech researchers develop a new biomaterial that could cure Type 1 diabetes

Insulin injections to treat Type 1 diabetes could become a thing of the past, but finding the cure faces many challenges.

4 Nov 2022

Novel liposomal nanovaccines strongly activate cellular immunity

Cancer immunotherapies, such as immune checkpoint inhibition therapy, have been attracting attention in recent years as new methods for treating cancer.

2 Nov 2022

UC Davis launches new center to accelerate the development of promising cancer therapies

UC Davis Comprehensive Cancer Center has launched a Center for Experimental Therapeutics in Cancer to accelerate promising cancer therapies from the lab to the bedside.

From The University of California, Davis 10 Oct 2022

Research shows readily available pharmaceutical manufacturing capacity in the United States

President Joe Biden signed an executive order Sept. 12 to launch a National Biotechnology and Biomanufacturing Initiative, noting the United States relies too heavily on foreign materials and foreign bioproduction.

5 Oct 2022

MD Anderson and Virogin Biotech collaborate to advance the development of investigational oncolytic viruses, treatments

The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.

12 Sep 2022

Yeast platform for the production of plant-derived anti-cancer drug

The supply of a plant-derived anti-cancer drug can finally meet global demand after a team of scientists from Denmark and the U.S. engineered yeast to produce the precursor molecules, which could previously only be obtained in trace concentrations in the native plant.

1 Sep 2022

Therapeutic mRNAs do not significantly impact translational fidelity

Synthetic mRNA therapeutics for the treatment and prevention of disease has attracted a lot of interest due to the exceptional efficacy of mRNA vaccinations against SARS-CoV-2.

30 Aug 2022

Mayo Clinic's strategic collaboration in biomanufacturing focuses on delivering novel biotherapeutics

Mayo Clinic today announced a strategic collaboration in biomanufacturing to deliver novel biotherapeutics for rare and complex conditions.

17 Aug 2022